Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature
Author
dc.contributor.author
Santa María, Pablo
Author
dc.contributor.author
Valenzuela, Fernando
Author
dc.contributor.author
Morales Huber, Claudia
Author
dc.contributor.author
Fuente Vera, Milton de la
Author
dc.contributor.author
Cullen, Roberto
Admission date
dc.date.accessioned
2018-10-31T13:27:02Z
Available date
dc.date.available
2018-10-31T13:27:02Z
Publication date
dc.date.issued
2017
Cita de ítem
dc.identifier.citation
Dermatology Reports 2017; volume 9:7079
es_ES
Identifier
dc.identifier.other
10.4081/dr.2017.7079
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/152330
Abstract
dc.description.abstract
We report the case of a 56-year old male with severe plaque psoriasis that was successfully treated with ixekizumab, a new anti interleukin (IL)-17 monoclonal antibody. During the first months of treatment he developed a lentiginous eruption in the sites of rapidly resolving plaques. Biopsy and immunohistochemistry reports showed elements of both lentigo and post-inflammatory hyper pigmentation. These findings, which have been increasingly described in anti-tumor necrosis factor alpha (TNF alpha) and anti IL-12/IL-23 therapy, may be explained by the down regulating effect of TNF alpha and IL-17 on pigmentation genes, which is very rapidly suppressed by ixekizumab, resulting in hyper pigmentation, and by the alteration of mesenchymal-epidermal interaction via keratinocyte growth factor during the inflammatory period, which results in the development of histopathological elements of lentigo.